Barry Rosen to Cohort Studies
This is a "connection" page, showing publications Barry Rosen has written about Cohort Studies.
Connection Strength
0.320
-
Altman AD, McGee J, May T, Lane K, Lu L, Xu W, Ghatage P, Rosen B. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. Gynecol Oncol. 2017 11; 147(2):257-261.
Score: 0.098
-
Whitworth PW, Beitsch PD, Patel R, Rosen B, Compagnoni G, Baron PL, Simmons R, Brown EA, Gold L, Holmes D, Smith LA, Kinney M, Grady I, Clark P, Barbosa K, Lyons S, Riley L, Coomer C, Curcio L, Ruiz A, Khan S, MacDonald H, Hughes K, Hardwick MK, Heald B, Munro SB, Nielsen SM, Esplin ED. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. JAMA Netw Open. 2022 09 01; 5(9):e2232787.
Score: 0.035
-
Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, Chi DS, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 2021 06 22; 118(25).
Score: 0.032
-
Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod SA, May T. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. Int J Gynaecol Obstet. 2021 Jun; 153(3):417-423.
Score: 0.031
-
Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA. Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. Int J Gynecol Cancer. 2020 06; 30(6):825-830.
Score: 0.030
-
Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM. Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation. JAMA Netw Open. 2019 08 02; 2(8):e198420.
Score: 0.028
-
McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecol Oncol. 2017 05; 145(2):346-351.
Score: 0.024
-
Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol. 2016 Jan; 140(1):42-7.
Score: 0.022
-
Bouchard-Fortier G, Rosen B, Vyarvelska I, Pasetka M, Covens A, Gien LT, Kupets R, Pulman K, Ferguson SE, Vicus D. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer. Gynecol Oncol. 2016 Jan; 140(1):36-41.
Score: 0.022